- Home
- CSCI vs BIAF Comparison
CSCI vs BIAF Comparison
Compare CSCI & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSCI
- BIAF
- Stock Information
- Founded
- CSCI 1990
- BIAF 2014
- Country
- CSCI Canada
- BIAF United States
- Employees
- CSCI N/A
- BIAF N/A
- Industry
- CSCI
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CSCI
- BIAF Health Care
- Exchange
- CSCI NYSE
- BIAF Nasdaq
- Market Cap
- CSCI 10.6M
- BIAF 12.2M
- IPO Year
- CSCI 1996
- BIAF 2022
- Fundamental
- Price
- CSCI $3.99
- BIAF $0.35
- Analyst Decision
- CSCI
- BIAF Hold
- Analyst Count
- CSCI 0
- BIAF 1
- Target Price
- CSCI N/A
- BIAF N/A
- AVG Volume (30 Days)
- CSCI 4.6K
- BIAF 12.3M
- Earning Date
- CSCI 08-12-2025
- BIAF 08-13-2025
- Dividend Yield
- CSCI N/A
- BIAF N/A
- EPS Growth
- CSCI N/A
- BIAF N/A
- EPS
- CSCI N/A
- BIAF N/A
- Revenue
- CSCI $9,030,000.00
- BIAF $8,809,228.00
- Revenue This Year
- CSCI N/A
- BIAF N/A
- Revenue Next Year
- CSCI N/A
- BIAF $20.00
- P/E Ratio
- CSCI N/A
- BIAF N/A
- Revenue Growth
- CSCI 36.51
- BIAF 78.40
- 52 Week Low
- CSCI $1.96
- BIAF $0.16
- 52 Week High
- CSCI $6.77
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- CSCI N/A
- BIAF 55.39
- Support Level
- CSCI N/A
- BIAF $0.27
- Resistance Level
- CSCI N/A
- BIAF $0.38
- Average True Range (ATR)
- CSCI 0.00
- BIAF 0.04
- MACD
- CSCI 0.00
- BIAF 0.00
- Stochastic Oscillator
- CSCI 0.00
- BIAF 69.05
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.